Brad Enerson
Executive Director, Head of Preclinical Safety @Kymera Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Executive Director, Head of Preclinical Safety @Kymera Therapeutics
Accountable for all aspects of Kymera’s nonclinical safety strategy in support of Kymera’s portfolio and proactively developing strategies to address unique challenges of small molecule degraders. Delivered timely and high quality nonclinical safety assessments on four clinical candidates: First-in-class IRAK-4 degrader, also first degrader for non-oncology indication First-in-class IRAK-4/IMiD degrader First-in-class STAT-3 degrader, also first clinical degrader targeting a transcription factor First-in-class MDM-2 degrader Supported multiple DC nominations and LO transitions Developed CRO strategy ensuring timely initiation and completion of nonclinical studies despite ongoing large animal shortages, while maintaining study quality Built out toxicology group with key hires (toxicologist, study manager, operations associate)
EDUCATION
University of Minnesota
PhD, Biochemistry and Molecular Biology
SKILLS
ABOUT BRAD ENERSON
Experienced nonclinical toxicologist and executive with recognized strategic leadership…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.